PlumeStars

PlumeStars is an Italian clinical-stage biopharmaceutical company specializing in the development of innovative drug delivery systems for pulmonary administration. As a spin-off from the University of Parma, the company focuses on orphan diseases and respiratory conditions, utilizing its proprietary technology to create high-dose dry powder inhalers. Their lead candidate, an inhalable cisplatin formulation for the treatment of lung cancer and mesothelioma, has received Orphan Drug Designation from both the EMA and FDA. The company's platform technology enables the delivery of large doses of medication directly to the lungs, improving therapeutic efficacy while reducing systemic side effects. PlumeStars also develops inhalable antibiotics and other treatments for chronic lung infections and cystic fibrosis. Their business model involves advancing internal programs through early clinical stages before seeking strategic partnerships for late-stage development and commercialization.